Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen Stock Slides 10 Percent on Missed Q2 Revenues

NEW YORK (GenomeWeb News) – Shares in Invitrogen were down approximately 9.8 percent, or $6.10, at $56.23 in mid-afternoon trading today after the company reported lower-than-expected revenues for the second quarter, and lowered its financial guidance.
 
As GenomeWeb News reported this morning, Invitrogen posted $313 million in total revenues for the quarter. Analysts had expected Invitrogen to report $320 million. The company now expects 2006 revenue to be between $1.26 billion and $1.30 billion, down from the $1.30 billion to $1.35 billion it projected in April.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.